MedTrace Logo

A New Approach of Neostigmine in Unavoidable Post Operative Ileus

NCT00676377 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2008-05-13

No results posted yet for this study

Summary

Postoperative ileus (POI) in the absence of any mechanical obstruction remains a commonly encountered clinical problem.So, this study aimed to show the effective way to decrease the rate of postoperative Ileus (POI).

Conditions

  • Ileus

Interventions

DRUG

Neostigmine

2.5 mg of neostigmine intravenously in 250 ml normal saline over a period of thirty minutes ,Half Life 3 Hours

DRUG

Saline

Saline Placebo

Sponsors & Collaborators

  • Baqiyatallah Medical Sciences University

    lead OTHER

Principal Investigators

  • S.Ahmad Fanaei, M.D. · Baqyiattalah University of Medical Science

  • S.Ali Ziaee, M.D. · Erfan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
76 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2007-12-31
Completion
2008-02-29

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00676377 on ClinicalTrials.gov